Clinical Trial Update: A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes [Phase 2]

View source ↗

Summary

Phase II open-label multicenter trial of cabazitaxel in patients with recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and tax…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)

Snippet

Sponsor: UNICANCER | Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 2 | Status: COMPLETED